News

Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders

December 13, 2023
Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator. This technology was licensed from Dr. Tejal Desai’s lab where...

Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

December 13, 2023
Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing. The oversubscribed round was led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with...

Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting

December 11, 2023
Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor (CAR) T cells at the American Society of...

Trial Library, oncology clinical trial technology company, announces release of provider decision support platform to advance access to trials in community oncology settings

December 08, 2023
Trial Library, Inc., an oncology clinical trials company, today announced it has launched a provider decision support platform to advance access to oncology clinical trials in community settings. The platform will support all oncology treatment clinical trials and has provided an initial release to...

Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy

December 08, 2023
Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample. In a new early detection study...

Autism’s Molecular Mechanisms Uncovered through Protein-Protein Interaction Network

December 07, 2023
This week, Nevan Krogan’s group posted a preprint describing a PPI network involving 100 ASD risk genes.

MindRhythm Completes Enrollment in its Multicenter Prehospital Trial for Identifying Large Vessel Occlusion Stroke

December 04, 2023
MindRhythm's EPISODE trial, the largest study of a prehospital stroke device in existence, has stopped enrolling new patients, has been closing down the sites, and is beginning to unblind the data for analysis. This is a very exciting milestone! Shortly they will reveal the results of the trial...

KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

December 04, 2023
KSQ Therapeutics, a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), today announced the Food and Drug Administration (FDA) has cleared an...

AskBio Announces First Patient Randomized in Phase 1 Trial of Gene Therapy for Multiple System Atrophy-Parkinsonian

November 21, 2023
“Enrolling the first patient in our REGENERATE MSA-101 trial is an important step in AskBio’s ongoing work to advance GDNF gene therapy,” said Krystof Bankiewicz, MD, PhD, Scientific Chair, Parkinson’s and MSA, AskBio. “The clinical advancement of AB-1005 for the treatment of MSA-P comes as we are...

Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners

November 14, 2023
Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations...

Pages